OWONWOHOW2SURVIVE Compartió un vínculo
2024-07-09 04:26:52 - Translate
"observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we .."
https://www.nature.com/articles/s41586-020-2814-7
"observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we .." https://www.nature.com/articles/s41586-020-2814-7
WWW.NATURE.COM
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses - Nature
In a phase I/II dose-escalation clinical trial, the mRNA COVID-19 vaccine BNT162b1 elicits specific T cell and antibody responses that suggest it has protective potential.
0 Commentarios 0 Acciones 496 Views 0 Vista previa
Please log in to like, share and comment!
© 2024 Sikhona Social Spanish
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Términos Privacidad Sikhona Social Support Contact Us